Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients randomized to the TID and BID dosing algorithmsa

From: Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

 

U500R TID (n = 162)

U500R BID (n = 163)

p value

Male, n (%)

83 (51.2)

89 (54.6)

.54

Race, n (%)

  

.66b

 White

133 (82.1)

133 (81.6)

 

 Black

21 (13.0)

19 (11.7)

 

 Asian

2 (1.2)

4 (2.5)

 

 Native American

3 (1.9)

1 (0.6)

 

 Other

3 (1.9)

6 (3.7)

 

Ethnicity (Hispanic), n (%)

32 (19.8)

30 (18.4)

.76

Age, yearsc

55.3 ± 10.5

55.5 ± 9.0

.86

Weight, kg

120.9 ± 25.1

122.9 ± 26.2

.48

BMI, kg/m2

41.8 ± 7.6

41.9 ± 7.3

.95

Baseline HbA1c

8.7 ± 1.1

8.7 ± 1.0

.87

Diabetes duration, years

14.9 ± 6.8

15.5 ± 8.0

.51

TDD, (U-100, final), units

287.1 ± 79.9

287.8 ± 81.2

.94

Number of injections, median [min, max]

5 [2, 9]

5 [2, 10]

.96

  1. Abbreviations: BID twice daily; BMI body mass index; HbA1 c glycated hemoglobin; TDD total daily dose; TID thrice daily
  2. p values for continuous variables are based on analysis of variance, and for categorical variables, Fisher’s exact or chi-square test
  3. aExcerpted from reference [3] Hood RC, et al. 2015
  4. bCombined values
  5. cValues are presented as means ± SD unless otherwise noted